Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.
Johnson & Johnson closed $22.62 below its 52-week high ($168.85), which the company achieved on September 4th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback